Cargando…

Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis

Tumour necrosis factor (TNF)-α is a key mediator of inflammation in rheumatoid arthritis, and its discovery led to the development of highly successful anti-TNF therapy. Subsequently, other biologic drugs targeting immune pathways, namely interleukin-6 blockade, B cell depletion, and T cell co-stimu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mulhearn, Ben, Barton, Anne, Viatte, Sebastien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963853/ https://www.ncbi.nlm.nih.gov/pubmed/31581724 http://dx.doi.org/10.3390/jpm9040046

Ejemplares similares

Genetics of rheumatoid arthritis susceptibility, severity, and treatment response
por: Viatte, Sebastien, et al.
Publicado: (2017)

Automated clustering reveals CD4(+) T cell subset imbalances in rheumatoid arthritis
por: Mulhearn, Ben, et al.
Publicado: (2023)

Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients
por: Viatte, Sebastien, et al.
Publicado: (2012)

Investigation of Caucasian rheumatoid arthritis susceptibility loci in African patients with the same disease
por: Viatte, Sebastien, et al.
Publicado: (2012)

Genotypic variability based association identifies novel non-additive loci DHCR7 and IRF4 in sero-negative rheumatoid arthritis
por: Wei, Wen-Hua, et al.
Publicado: (2017)

Predicting treatment response to IL6R blockers in rheumatoid arthritis
por: Nouri, Bako, et al.
Publicado: (2020)

Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy
por: Barton, Jennifer L
Publicado: (2009)

Bone Effects of Biologic Drugs in Rheumatoid Arthritis
por: Corrado, Addolorata, et al.
Publicado: (2013)

Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis
por: Smith, Samantha Louise, et al.
Publicado: (2023)

Polymorphisms Involved in Response to Biological Agents Used in Rheumatoid Arthritis
por: Pallio, Giovanni, et al.
Publicado: (2020)

Loci associated with N-glycosylation of human IgG are not associated with rheumatoid arthritis: a Mendelian randomisation study
por: Yarwood, Annie, et al.
Publicado: (2015)

Towards Personalising the Use of Biologics in Rheumatoid Arthritis: A Discrete Choice Experiment
por: Vass, Caroline M, et al.
Publicado: (2021)

The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis
por: Perry, Martin, et al.
Publicado: (2020)

Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics
por: Maciejewski, Mateusz, et al.
Publicado: (2021)

Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies
por: Bitoun, Samuel, et al.
Publicado: (2023)

Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?
por: Jani, Meghna, et al.
Publicado: (2019)

Novel Rheumatoid Arthritis Susceptibility Locus at 22q12 Identified in an Extended UK Genome-Wide Association Study
por: Orozco, Gisela, et al.
Publicado: (2014)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Immunophenotype and functional characteristics of rheumatoid arthritis derived myeloid dendritic cells and plasmacytoid dendritic cells
por: Jongbloed, S, et al.
Publicado: (2005)

Genetics of rheumatoid arthritis contributes to biology and drug discovery
por: Okada, Yukinori, et al.
Publicado: (2013)

Response measures influence comparative effectiveness of biological drugs in rheumatoid arthritis
por: Canhao, Helena, et al.
Publicado: (2012)

Rationale of using different biological therapies in rheumatoid arthritis
por: Geyer, Matthias, et al.
Publicado: (2010)

A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study
por: Jiang, Xia, et al.
Publicado: (2016)

Biologic monotherapy in the treatment of rheumatoid arthritis
por: Detert, Jacqueline, et al.
Publicado: (2015)

Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy
por: Sutcliffe, Megan, et al.
Publicado: (2022)

Major histocompatibility complex harbors widespread genotypic variability of non-additive risk of rheumatoid arthritis including epistasis
por: Wei, Wen-Hua, et al.
Publicado: (2016)

Drug-microbiota interactions and treatment response: Relevance to rheumatoid arthritis
por: Sayers, Ellie, et al.
Publicado: (2018)

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
por: Wang, Susan Siyu, et al.
Publicado: (2023)

Administration costs of intravenous biologic drugs for rheumatoid arthritis
por: Soini, Erkki J, et al.
Publicado: (2013)

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician
por: Findeisen, Kate E, et al.
Publicado: (2021)

Treatment with Biologicals in Rheumatoid Arthritis: An Overview
por: Rein, Philipp, et al.
Publicado: (2017)

Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?
por: Nagy, György, et al.
Publicado: (2015)

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
por: Bonek, Krzysztof, et al.
Publicado: (2021)

Prediction of treatment response in rheumatoid arthritis patients using genome‐wide SNP data
por: Cherlin, Svetlana, et al.
Publicado: (2018)

Biological Basis for the Use of Botanicals in Osteoarthritis and Rheumatoid Arthritis: A Review
por: Ahmed, Salahuddin, et al.
Publicado: (2005)

Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
por: Lim, Heejin, et al.
Publicado: (2018)

Positive Effects of Biologics on Osteoporosis in Rheumatoid Arthritis
por: Kim, Yunkyung, et al.
Publicado: (2023)

Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis
por: Choy, Ernest H
Publicado: (2019)

Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
por: Romão, Vasco C., et al.
Publicado: (2017)

Wnt Signaling and Biological Therapy in Rheumatoid Arthritis and Spondyloarthritis
por: Cici, Daniela, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3e00vkp86ni99j7mkp3sc2m8in